115 related articles for article (PubMed ID: 3611952)
1. Antigenic identification of chemotactic factor inactivator in normal human serum and bronchoalveolar lavage fluid.
Robbins RA; Rasmussen JK; Clayton ME; Gossman GL; Kendall TJ; Rennard SI
J Lab Clin Med; 1987 Sep; 110(3):292-9. PubMed ID: 3611952
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of chemotactic factor inactivator by cigarette smoke. A potential mechanism of modulating neutrophil recruitment to the lung.
Robbins RA; Gossman GL; Nelson KJ; Koyama S; Thompson AB; Rennard SI
Am Rev Respir Dis; 1990 Oct; 142(4):763-8. PubMed ID: 2221580
[TBL] [Abstract][Full Text] [Related]
3. Functional loss of chemotactic factor inactivator in the adult respiratory distress syndrome.
Robbins R; Maunder R; Gossman G; Kendall T; Hudson L; Rennard S
Am Rev Respir Dis; 1990 Jun; 141(6):1463-8. PubMed ID: 2350087
[TBL] [Abstract][Full Text] [Related]
4. Chemotactic factor inactivator interaction with Gc-globulin (vitamin D-binding protein). A mechanism of modulating the chemotactic activity of C5a.
Robbins RA; Hamel FG
J Immunol; 1990 Mar; 144(6):2371-6. PubMed ID: 2313096
[TBL] [Abstract][Full Text] [Related]
5. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity.
Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI
J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869
[TBL] [Abstract][Full Text] [Related]
6. Elevation of chemotactic factor inactivator in alcoholic liver disease.
Robbins RA; Zetterman RK; Kendall TJ; Gossman GL; Monsour HP; Rennard SI
Hepatology; 1987; 7(5):872-7. PubMed ID: 3653852
[TBL] [Abstract][Full Text] [Related]
7. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity.
Fick RB; Robbins RA; Squier SU; Schoderbek WE; Russ WD
Pediatr Res; 1986 Dec; 20(12):1258-68. PubMed ID: 3540828
[TBL] [Abstract][Full Text] [Related]
8. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B.
Perez HD; Hooper C; Volanakis J; Ueda A
J Immunol; 1987 Jul; 139(2):484-9. PubMed ID: 3648093
[TBL] [Abstract][Full Text] [Related]
10. Role of chemotactic factor inactivation in neutrophil chemotaxis.
Tannous R; Cavender-Zylich N; Ginsberg BH
J Lab Clin Med; 1981 Aug; 98(2):238-50. PubMed ID: 7252332
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the anaphylatoxin inactivator and chemotactic factor inactivator activities during cardiopulmonary bypass.
Kreutzer DL; McCormick JR; Despins A; Moore M; Rousou JH; Dobbs W; Engleman RN
J Exp Pathol; 1984; 1(3):183-7. PubMed ID: 6336305
[TBL] [Abstract][Full Text] [Related]
12. Production of C5a antagonist by synovial and peritoneal tissue fibroblasts.
Matzner Y; Gavison R; Shlomai Z; Ben-Bassat H; Liebergal M; Robinson DR; Babior BM
J Cell Physiol; 1986 Nov; 129(2):215-20. PubMed ID: 3771654
[TBL] [Abstract][Full Text] [Related]
13. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
[TBL] [Abstract][Full Text] [Related]
14. A C5a inhibitor in peritoneal fluid.
Matzner Y; Brzezinski A
J Lab Clin Med; 1984 Feb; 103(2):227-35. PubMed ID: 6693795
[TBL] [Abstract][Full Text] [Related]
15. Identification of neutrophil chemotactic factors in bronchoalveolar lavage fluid of asthmatic patients.
Teran LM; Campos MG; Begishvilli BT; Schröder JM; Djukanovic R; Shute JK; Church MK; Holgate ST; Davies DE
Clin Exp Allergy; 1997 Apr; 27(4):396-405. PubMed ID: 9146932
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the chemotactic activity of human C5a des Arg by an anionic polypeptide ("cochemotaxin") in normal serum and plasma.
Perez HD; Goldstein IM; Webster RO; Henson PM
J Immunol; 1981 Feb; 126(2):800-4. PubMed ID: 7451994
[TBL] [Abstract][Full Text] [Related]
17. Serum inhibitors of leukocyte chemotaxis in Crohn's disease and ulcerative colitis.
Rhodes JM; Potter BJ; Brown DJ; Jewell DP
Gastroenterology; 1982 Jun; 82(6):1327-34. PubMed ID: 6978274
[TBL] [Abstract][Full Text] [Related]
18. Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide.
Shingu M; Nobunaga M
Am J Pathol; 1984 Nov; 117(2):201-6. PubMed ID: 6388344
[TBL] [Abstract][Full Text] [Related]
19. Studies of human C5a as a mediator of inflammation in normal human skin.
Yancey KB; Hammer CH; Harvath L; Renfer L; Frank MM; Lawley TJ
J Clin Invest; 1985 Feb; 75(2):486-95. PubMed ID: 2982914
[TBL] [Abstract][Full Text] [Related]
20. Biochemical quantitation of the chemotactic factor inactivator activity in human serum.
Fantone J; Senior RM; Kreutzer DL; Jones M; Ward PA
J Lab Clin Med; 1979 Jan; 93(1):17-24. PubMed ID: 759526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
